Human immune response to a plague vaccine comprising recombinant F1 and V antigens

被引:145
作者
Williamson, ED [1 ]
Flick-Smith, HC [1 ]
LeButt, C [1 ]
Rowland, CA [1 ]
Jones, SM [1 ]
Waters, EL [1 ]
Gwyther, RJ [1 ]
Miller, J [1 ]
Packer, PJ [1 ]
Irving, M [1 ]
机构
[1] Dstl Porton Down, Salisbury SP4 0JQ, Wilts, England
关键词
D O I
10.1128/IAI.73.6.3598-3608.2005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The human immune response to a new recombinant plague vaccine, comprising recombinant F1 (rF1) and rV antigens, has been assessed during a phase 1 safety and immunogenicity trial in healthy volunteers. All the subjects produced specific immunoglobulin G (IgG) in serum after the priming dose, which peaked in value after the booster dose (day 21), with the exception of one individual in the lowest dose level group, who responded to rF1 only. Three subjects, found to have an anti-rV titer at screening, were excluded from the overall analysis. Human antibody functionality has been assessed by quantification of antibody competing for binding to rV in vitro and also by the transfer of protective immunity in human serum into the naive mouse. Human and macaque IgG competed for binding to rV in vitro with a mouse monoclonal antibody, previously shown to protect mice against challenge with plague, suggesting that this protective B-cell epitope on rV is conserved between these three species. Total IgG to rV in individuals and the titer of IgG competing for binding to rV correlated significantly at days 21 (r = 0.72; P < 0.001) and 28 (r = 0.82; P < 0.001). Passive transfer of protective immunity into mice also correlated significantly with total IgG titer to rF1 plus rV at days 21 (r(2) = 98.6%; P < 0.001) and 28 (r(2) = 76.8%; P < 0.03). However, no significant vaccination-related change in activation of peripheral blood mononuclear cells was detected at any time. Potential serological immune correlates of protection have been investigated, but no trends specific to vaccination could be detected in cellular markers.
引用
收藏
页码:3598 / 3608
页数:11
相关论文
共 32 条
  • [1] Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis
    Anderson, GW
    Leary, SEC
    Williamson, ED
    Titball, RW
    Welkos, SL
    Worsham, PL
    Friedlander, AM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (11) : 4580 - 4585
  • [2] Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge
    Andrews, GP
    Heath, DG
    Anderson, GW
    Welkos, SL
    Friedlander, AM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (06) : 2180 - 2187
  • [3] BARTELLO.PJ, 1973, MIL MED, V138, P720
  • [4] Therapeutic antibodies for human diseases at the dawn of the twenty-first century
    Brekke, OH
    Sandlie, I
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (01) : 52 - 62
  • [5] CAVANAUGH DC, 1974, J INFECT DIS, V128, pS37
  • [6] The SCID/Beige mouse as a model to investigate protection against Yersinia pestis
    Green, M
    Rogers, D
    Russell, P
    Stagg, AJ
    Bell, DL
    Eley, SM
    Titball, RW
    Williamson, ED
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1999, 23 (02): : 107 - 113
  • [7] Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine
    Heath, DG
    Anderson, GW
    Mauro, JM
    Welkos, SL
    Andrews, GP
    Adamovicz, J
    Friedlander, AM
    [J]. VACCINE, 1998, 16 (11-12) : 1131 - 1137
  • [8] Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization
    Hill, J
    Leary, SEC
    Griffin, KF
    Williamson, ED
    Titball, RW
    [J]. INFECTION AND IMMUNITY, 1997, 65 (11) : 4476 - 4482
  • [9] Janeway C.A., 1999, IMMUNOBIOLOGY
  • [10] JEFFERSON TW, 2001, COCHRANE LIBR, V4